Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Todd Neale

August 27, 2016

News Daily News

Decline Seen in Readmissions After PCI in the Medicare Population

Todd Neale

July 21, 2016

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Conference News ESC 2012

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Yael L. Maxwell

August 29, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular Stories for October 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Decline Seen in Readmissions After PCI in the Medicare Population

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

肺栓塞发作后，二级抗凝效果未持续

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content